RNAi技術市場規模、佔有率和成長分析：按分子類型、遞送技術、應用領域、終端用戶產業和地區分類－2026-2033年產業預測

2024 年全球 RNAi 技術市場價值為 35.8 億美元，預計到 2025 年將成長至 41.2 億美元，到 2033 年將成長至 127.9 億美元，在預測期（2026-2033 年）內複合年成長率為 15.2%。

RNAi技術市場專注於序列特異性基因靜默，其應用涵蓋治療、科研試劑和農業等領域，主要驅動力在於其能夠影響難治性疾病的路徑。先進的遞送技術，包括脂質奈米顆粒和GalNAc偶聯物，是關鍵的成長驅動力，它們透過提高標靶精度和最大限度地減少全身暴露，解決了安全性問題，並促進了臨床檢驗。成功的藥物獲批提振了投資者的信心，促成了在循環系統和腫瘤學等多個領域的合作和產品組合的擴展。此外，人工智慧（AI）正在透過簡化標靶識別、最佳化siRNA序列設計和增強候選化合物優先排序，革新RNAi藥物發現。 RNAi開發公司與人工智慧公司之間的合作有望加速商業化進程，並最大限度地提高這個充滿活力的領域的商機。

全球RNAi技術市場按分子類型、遞送技術、應用領域、終端用戶產業和地區進行細分。依分子類型分類，市場分為siRNA、miRNA、shRNA和其他類型。依遞送技術分類，市場分為脂質奈米顆粒、聚合物和偶聯系統、病毒載體、新興奈米材料。按應用領域分類，市場分為治療、藥物發現與篩檢、診斷、農業。按終端用戶產業分類，市場分為製藥和生物技術公司、合約開發和生產組織（CDMO）、學術和研究機構以及診斷檢查室。依地區分類，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球RNAi技術市場的成長要素

全球RNAi技術市場正受到奈米顆粒載體、脂質製劑和結合化學領域創新技術的顯著推動，這些創新技術拓展了RNAi療法可有效靶向的組織範圍。這些進步降低了遞送障礙，並提高了臨床可行性。增強的遞送平台透過降低技術門檻、提供更可預測的藥物動力學和生物分佈，增強了研發人員和投資者的信心。這有助於研究專案從概念階段更順利地過渡到臨床前檢驗，使與合約開發商的合作更具吸引力，並使整個研發管線更加多元化。所有這些因素都促進了市場的持續成長。

全球RNAi技術市場面臨的限制因素

全球RNAi技術市場面臨許多限制因素，包括新型RNAi產品評估的不確定性以及各地監管要求的差異。這些差異會導致研發週期延長，並加重申辦方的認知和管理負擔。由於需要創新的生產控制和生物分佈研究，除了需要複雜的長期安全性證明標準外，還需要全面的臨床前和臨床數據。這可能會阻礙小規模開發商的參與，並阻礙其產品組合的擴展。此外，應對不同的法規結構會增加成本，並使全球研發策略更加複雜。結果是，企業採取謹慎的投資策略，延遲市場進入，並保守地確定專案優先級，最終阻礙了整個市場的發展。

全球RNAi技術市場趨勢

全球RNAi技術市場正呈現先進遞送方式發展的顯著趨勢，主要得益於奈米顆粒工程和結合化學領域的創新。這一發展趨勢推動了非侵入性、標靶性載體的研發，進而改善RNAi療法的藥物動力學，提高患者依從性和組織特異性。各公司正與遞送技術專家進行策略合作，以應對臨床應用中的挑戰，並開發出滿足不同需求的客製化製劑。隨著實際應用案例和模組化遞送工具包的不斷積累，業界有望縮短研發週期，將RNAi的應用範圍擴展至眾多疾病領域，並鞏固其在治療領域變革性力量的地位。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球RNAi技術市場規模：依分子類型分類

• siRNA
• miRNA
• shRNA
• 其他

全球RNAi技術市場規模：按遞送技術分類

• 脂質奈米顆粒
  • 可電離的脂質奈米顆粒
  • 脂質體
• 聚合物和共軛體系
  • GalNAc 綴合物
  • 聚乙二醇化載體
• 病毒載體
  • 腺結合病毒
  • 慢病毒載體
• 新興奈米材料

全球RNAi技術市場規模：按應用領域分類

• 治療
  • 腫瘤學
  • 心血管代謝疾病
  • 感染疾病
  • 神經系統疾病與罕見遺傳疾病
• 藥物發現與篩檢
• 診斷
• 農業

全球RNAi技術市場規模：依最終用途產業分類

• 製藥和生物技術公司
• 合約開發和製造組織
• 學術研究機構
• 診斷檢查室

全球RNAi技術市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Alnylam Pharmaceuticals
• Arrowhead Pharmaceuticals
• Ionis Pharmaceuticals
• Dicerna Pharmaceuticals
• Silence Therapeutics
• Quark Pharmaceuticals
• Gradalis
• Sylentis
• Sirnaomics
• Thermo Fisher Scientific
• Merck KGaA
• Qiagen
• Danaher Corporation
• Agilent Technologies
• Bio-Rad Laboratories
• GenScript Biotech
• Takara Bio
• Promega Corporation
• Horizon Discovery
• System Biosciences

結論與建議

Global Rnai Technology Market size was valued at USD 3.58 Billion in 2024 and is poised to grow from USD 4.12 Billion in 2025 to USD 12.79 Billion by 2033, growing at a CAGR of 15.2% during the forecast period (2026-2033).

The RNAi technology market focuses on sequence-specific gene silencing across therapeutics, research reagents, and agricultural applications, with its primary catalyst being the capacity to influence challenging disease pathways. Enhanced delivery technologies, including lipid nanoparticles and GalNAc conjugates, are crucial growth enhancers, facilitating improved targeting and minimizing systemic exposure, which have addressed safety concerns and enabled clinical validation. Successful drug approvals have spurred increased investor confidence, leading to partnerships and expanded portfolios in diverse fields such as cardiology and oncology. Additionally, artificial intelligence is revolutionizing RNAi drug discovery by streamlining target identification, optimizing siRNA sequence design, and enhancing candidate prioritization. The collaboration between RNAi developers and AI firms is poised to accelerate commercialization and maximize revenue opportunities in this dynamic sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Rnai Technology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Rnai Technology Market Segments Analysis

The global RNAi technology market is segmented by molecule type, delivery technology, application area, end-use industry and region. Based on molecule type, the market is segmented into siRNA, miRNA, shRNA and Others. Based on delivery technology, the market is segmented into Lipid Nanoparticles, Polymer & Conjugate Systems, Viral Vectors and Emerging Nanomaterials. Based on application area, the market is segmented into Therapeutics, Drug Discovery & Screening, Diagnostics and Agriculture. Based on end-use industry, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Development & Manufacturing Organizations, Academic & Research Institutes and Diagnostic Laboratories. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Rnai Technology Market

The global RNAi technology market is significantly driven by innovations in nanoparticle carriers, lipid formulations, and conjugation chemistries, which have expanded the range of tissues that RNAi therapeutics can effectively target. These advancements minimize delivery obstacles and enhance clinical viability. Enhanced delivery platforms instill greater confidence among developers and investors by lowering technical barriers and providing more predictable pharmacokinetics and biodistribution. This encourages a smoother transition from conceptual ideas to preclinical validation in research initiatives, making collaborations with contract developers more appealing and diversifying the overall pipeline, all contributing to sustained growth in the market.

Restraints in the Global Rnai Technology Market

The global RNAi technology market faces significant constraints stemming from uncertainties in evaluating novel RNAi products and the varying regulatory requirements across different regions. These disparities can result in prolonged development timelines and place a heavier cognitive and administrative burden on sponsors. The intricate criteria for proving long-term safety, alongside demands for innovative manufacturing controls and biodistribution studies, necessitate comprehensive preclinical and clinical data, which may deter smaller developers and hinder portfolio growth. Additionally, navigating diverse regulatory frameworks increases costs and complicates global development strategies, resulting in cautious investment approaches, delayed market entry, and a conservative focus on program prioritization that ultimately hampers overall market progress.

Market Trends of the Global Rnai Technology Market

The global RNAi technology market is witnessing a notable trend towards advanced delivery modalities, driven by innovations in nanoparticle engineering and conjugation chemistries. This evolution enables the development of noninvasive and targeted carriers that enhance the pharmacokinetics of RNAi therapeutics, improving patient compliance and tissue specificity. Companies are strategically collaborating with delivery specialists to address clinical translation challenges, resulting in a diverse range of tailored formulations. As real-world applications and modular delivery toolkits accumulate, the industry anticipates accelerated development timelines, expanding the reach of RNAi across numerous disease areas and solidifying its position as a transformative force in therapeutics.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global RNAI Technology Market Size by Molecule Type & CAGR (2026-2033)

• Market Overview
• siRNA
• miRNA
• shRNA
• Others

Global RNAI Technology Market Size by Delivery Technology & CAGR (2026-2033)

• Market Overview
• Lipid Nanoparticles
  • Ionizable LNPs
  • Liposomes
• Polymer & Conjugate Systems
  • GalNAc Conjugates
  • PEGylated Carriers
• Viral Vectors
  • Adeno-Associated Virus
  • Lentiviral Vectors
• Emerging Nanomaterials

Global RNAI Technology Market Size by Application Area & CAGR (2026-2033)

• Market Overview
• Therapeutics
  • Oncology
  • Cardiometabolic Disorders
  • Infectious Diseases
  • Neurological & Rare Genetic Disorders
• Drug Discovery & Screening
• Diagnostics
• Agriculture

Global RNAI Technology Market Size by End-Use Industry & CAGR (2026-2033)

• Market Overview
• Pharmaceutical & Biotechnology Companies
• Contract Development & Manufacturing Organizations
• Academic & Research Institutes
• Diagnostic Laboratories

Global RNAI Technology Market Size & CAGR (2026-2033)

• North America (Molecule Type, Delivery Technology, Application Area, End-Use Industry)
  • US
  • Canada
• Europe (Molecule Type, Delivery Technology, Application Area, End-Use Industry)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Molecule Type, Delivery Technology, Application Area, End-Use Industry)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Molecule Type, Delivery Technology, Application Area, End-Use Industry)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Molecule Type, Delivery Technology, Application Area, End-Use Industry)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Alnylam Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arrowhead Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dicerna Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Silence Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quark Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gradalis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sylentis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sirnaomics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenScript Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Promega Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Discovery
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• System Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations